ECO-STAR PRO SILK
Informasi Utama
- Nama dagang:
- ECO-STAR PRO SILK
- Tersedia dari:
- ECOLAB DEUTSCHLAND GMBH
- Digunakan untuk:
- manusia
- Jenis Obat:
- Perangkat medis
Dokumen
- untuk profesional kesehatan:
- Ringkasan karakteristik Produk
-
- untuk masyarakat umum:
- Informasi leaflet untuk produk ini saat ini tidak tersedia, Anda dapat mengirim permintaan untuk layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami mampu mendapatkannya.
Meminta selebaran informasi untuk masyarakat umum.
Lokalisasi
- Tersedia di:
-
Indonesia
- Bahasa:
- Bahasa Indonesia
Informasi lainnya
Status
- Sumber:
- Ecolab
- Nomor Otorisasi:
- 903422-01
- Pembaharuan Terakhir:
- 12-03-2018
Ringkasan karakteristik Produk: dosis, interaksi, efek samping
ECO-STAR PRO SILK
Pelembut Binatu
LEMBAR DATA KEAMANAN
Nama produk
Penggunaan dan
pembatasan yang
direkomendasikan
Nomor telepon darurat
:
:
Informasi pemasok
:
ECO-STAR PRO SILK
Gunakan hanya untuk tujuan pada label produk.
:
Bagian 1. Identifikasi produk kimia dan perusahaan
Nama-nama lain
:
Tidak ada.
Informasi pengenceran
produk
:
0.04 - 0.13%
PT. Ecolab Indonesia
Jl. Jababeka XII Kav V-37
Kawasan Industri jababeka, Cikarang
Indonesia 17350
Tel : (62-21) 5707557 Fax : (62-21) 5707682
+1 651-222-5352
KOROSI/IRITASI KULIT - 3
IRITASI/ KERUSAKAN PARAH PADA MATA -
BAHAYA TOKSISITAS AKUT PADA
LINGKUNGAN AKUATIK - 2
BAHAYA TOKSISITAS KRONIK PADA
LINGKUNGAN AKUATIK - 2
Klasifikasi GHS
(Globally
Harmonised System
~ Sistim Harmonisasi
Global)
:
Kata sinyal
:
Berbahaya
Pernyataan bahaya
:
Menyebabkan kerusakan serius pada mata.
Menyebabkan iritasi kulit ringan.
Beracun terhadap kehidupan akuatik dengan
efek jangka panjang.
Piktogram
:
Pernyataan kehati-hatian
Pencegahan
:
Kenakan pelindung mata atau wajah. Hindari
pelepasan ke lingkungan. Cuci tangan dengan
bersih setelah penanganan.
Tanggapan
:
Kumpulkan tumpahan. Jika terjadi iritasi kulit:
Dapatkan nasihat medis. JIKA TERKENA
MATA: Bilas secara hati-hati dengan air
selama beberapa menit. Lepaskan lensa
kontak jika memakainya dan mudah dilakukan.
Lanjutkan membilas. Segera hubungi Pusat
Penanggulangan Keracunan atau tenaga
medis.
2. Identifikasi Bahaya
Elemen label GHS
Produk TERJUAL
Penggunaan produk dicairkan
Tidak diklasifikasikan.
Tanpa Kata Sinyal
Tidak diketahui efek signifikan atau bahaya
kritis.
Cuci sepenuhnya sesudah penanganan.
Tidak berlaku.
903422-01
Halaman: 1/7
ECO-STAR PRO SILK
2. Identifikasi Bahaya
Penyimpanan
:
Tidak teridentifikasi adanya tindakan khusus
lainnya.
Pembuangan
:
Buang isi dan wadah sesuai dengan peraturan
lokal, regional, nasional dan internasional.
Bahaya lain
:
Tidak diketahui.
Tidak teridentifikasi adanya tindakan khusus
lainnya.
Tidak berlaku.
Tidak diketahui.
Campuran
3. Komposisi/ Informasi tentang Bahan Penyusun Senyawa tunggal
Zat/sediaan
:
Senyawa amonium kuaterner
1 - 10
61789-80-8
ISOPROPIL ALKOHOL
1 - 10
67-63-0
Komponen-komponen yang berbahaya
Nomor CAS
Rentang konsentrasi (%)
Produk TERJUAL
Penggunaan produk dicairkan
Tidak terdapat bahan yang, sejauh pengetahuan pemasok saat ini dan pada konsentrasi yang berlaku,
diklasifikasikan sebagai berbahaya pada kesehatan atau lingkungan dan karenanya diperlukan pelaporan dalam
bagian ini.
Dapatkan pertolongan medis jika terjadi gejala.
Bilas secara hati-hati dengan air selama
beberapa menit. Lepaskan lensa kontak jika
memakainya dan mudah dilakukan. Lanjutkan
membilas. Segera dapatkan pertolongan medis.
Bilas dengan air beberapa menit. Jika terjadi
iritasi kulit: Dapatkan pertolongan medis.
Tidak perlu tindakan khusus. Obati berdasarkan
gejala.
Kontak mata
Kontak kulit
Penghirupan
Tertelan
:
:
:
:
Perlindungan bagi
penolong pertama
:
Tidak boleh melakukan tindakan yang menyangkut risiko pribadi atau tanpa pelatihan yang
sesuai. Mungkin dapat membahayakan bagi orang yang memberikan pertolongan resusitasi dari
mulut-ke-mulut. Cuci pakaian yang terkontaminasi dengan air sampai bersih sebelum
melepaskannya, atau memakai sarung tangan.
Catatan untuk
dokter
:
Jika terhirup produk uraian dalam kebakaran, gejalanya mungkin tertunda. Orang yang terkena
mungkin harus terus berada dalam pengamatan medis selama 48 jam.
Lihat informasi toksikologi (bagian 11)
4. Tindakan Pertolongan Pertama
Produk TERJUAL
Penggunaan produk dicairkan
Efek setelah terkena mata tidak diketahui.
Bilas dengan air selama beberapa menit.
Efek setelah terkena kulit tidak diketahui.
Bilas dengan air selama beberapa menit.
Tidak perlu tindakan khusus. Obati
berdasarkan gejala.
Dapatkan pertolongan medis jika terjadi
gejala.
Bahaya spesifik yang
diakibatkan bahan kimia
tersebut
Dalam kebakaran atau jika dipanaskan, peningkatan tekanan akan terjadi dan
wadah bisa meledak. Bahan ini toksik bagi kehidupan air dengan efek yang
berakhir lama. Air bekas memadamkan kebakaran yang tercemar dengan bahan
ini harus dibendung dan dicegah agar tidak mengalir masuk/dibuang ke saluran air,
parit, atau selokan.
Gunakan semprotan air, kabut atau busa.
:
Media yang sesuai untuk
pemadaman kebakaran
:
5. Tindakan Pemadaman Kebakaran
Produk TERJUAL
903422-01
Halaman: 2/7
ECO-STAR PRO SILK
5. Tindakan Pemadaman Kebakaran
Jika ada kebakaran segera isolasi tempat kejadian dengan menjauhkan semua
orang dari lokasi kebakaran. Tidak boleh melakukan tindakan yang menyangkut
risiko pribadi atau tanpa pelatihan yang sesuai.
Produk dekomposisi termal
berbahaya
Bahan-bahan berikut ini mungkin dapat termasuk golongan produk penguraian-
hayati:
karbon dioksida
karbon monoksida
oksida nitrogen
senyawa berhalogen
Petugas pemadam kebakaran harus memakai perlengkapan pelindung yang
memadai dan alat bantu pernapasan (Self-Contained Breathing Apparatus - SCBA)
yang berpelindung-wajah penuh dan yang beroperasi dalam mode tekanan positif.
Alat pelindung khusus
untuk petugas pemadam
kebakaran
:
:
:
Langkah-langkah
pencegahan bagi
lingkungan
Tindakan
pencegahan pribadi
:
:
Segera laksanakan prosedur perusahaan untuk
menanggulangi tumpahan. Jauhkan orang-orang
dari tepat tumpahan. Kenakan perlengkapan
pelindung pribadi yang layak (lihat bagian 8).
Jangan menyentuh atau berjalan kaki melintasi
tumpahan bahan.
Jaga agar tumpahan bahan dalam jumlah
banyak tidak mengalir ke tanah dan saluran air di
permukaan tanah.
Gunakan air bilas untuk pembersihan akhir.
Metode untuk
membersihan
:
6. Tindakan Penanggulangan jika terjadi Kebocoran
Produk TERJUAL
Penggunaan produk dicairkan
Gunakan alat pelindung diri sesuai
kebutuhan.
Jaga agar tumpahan bahan dalam jumlah
banyak tidak mengalir ke tanah dan saluran
air di permukaan tanah.
Gunakan air bilas untuk pembersihan akhir.
Menangani/
Penanganan
Penyimpanan
Jangan terkena mata atau kulit atau pakaian.
Jangan menghirup uap atau kabut. Gunakan
hanya dengan ventilasi yang memadai. Cuci
sepenuhnya sesudah penanganan.
Jauhkan dari jangkauan anak-anak. Pastikan
wadah tertutup rapat.
:
:
7. Penanganan dan Penyimpanan
Produk TERJUAL
Penggunaan produk dicairkan
Cuci sepenuhnya sesudah penanganan.
Jauhkan dari jangkauan anak-anak.
Simpan dalam suhu antara: 15 dan 45°C
Parameter pengendalian
8. Kontrol Paparan/Perlindungan Diri
ISOPROPIL ALKOHOL
ACGIH TLV (Amerika Serikat, 3/2012).
STEL: 400 ppm 15 menit.
TWA: 200 ppm 8 jam.
Nama bahan
Batas pemaparan
903422-01
Halaman: 3/7
ECO-STAR PRO SILK
8. Kontrol Paparan/Perlindungan Diri
Perlindungan
tangan
Tidak diperlukan respirator dalam kondisi normal
dan kondisi yang ditentukan untuk penggunaan
produk.
Tidak ada peralatan pelindung yang dibutuhkan
dalam kondisi pemakaian normal.
Gunakan kacamata pelindung. Selanjutnya
gunakan pelindung wajah.
Perlindungam mata
Perlindungan
pernapasan
:
:
:
Perlindungan kulit
Tidak ada peralatan pelindung yang dibutuhkan
dalam kondisi pemakaian normal.
:
Pengendalian teknik
yang sesuai
:
Gunakan hanya dengan ventilasi yang memadai.
Jika pengoperasian pemakai menimbulkan debu,
asap, gas, uap atau kabut, gunakan daerah kerja
terkurung, ventilasi pembuangan lokal atau
kontrol teknis lainnya untuk menjaga agar
pekerja tidak terbuka terhadap kontaminan
terbawa-udara di atas batas yang
direkomendasikan atau ketentuan hukum.
Menyediakan fasilitas untuk cepat membasahi
atau pembilasan pada mata dan tubuh pada
kasus kontak atau bahaya lain.
Cuci tangan, lengan dan wajah sampai bersih setelah menangani produk kimia, sebelum
makan, merokok dan menggunakan WC dan seusai waktu kerja. Teknik yang sesuai harus
digunakan untuk melepaskan/membuang pakaian berpotensi terkontaminasi. Cuci pakaian
yang terkontaminasi sebelum dipakai kembali.
Tindakan higienis
:
Perlindungan perorangan
Produk TERJUAL
Penggunaan produk dicairkan
Ventilasi umum yang baik semestinya cukup
untuk mengendalikan pemaparan pekerja
terhadap kadar kontaminasi yang terbawa-
udara.
Tidak ada peralatan pelindung yang
dibutuhkan dalam kondisi pemakaian normal.
Tidak ada peralatan pelindung yang
dibutuhkan dalam kondisi pemakaian normal.
Tidak diperlukan respirator dalam kondisi
normal dan kondisi yang ditentukan untuk
penggunaan produk.
Tidak ada peralatan pelindung yang
dibutuhkan dalam kondisi pemakaian normal.
Bentuk fisik
Titik lebur
Tekanan uap
Kerapatan relatif
Rapat uap
Kelarutan
Cairan.
Tidak tersedia.
0.95 sampai dengan 1.01 (Air = 1)
Tidak tersedia.
Tidak tersedia.
Tidak tersedia.
Mirip-wewangian
Bau
pH
Hijau [Terang]
Warna
Laju penguapan
(butil asetat = 1)
Tidak tersedia.
Suhu dapat
membakar sendiri
(auto-ignition)
Titik nyala
Tidak tersedia.
> 100°C
Tidak tersedia.
4.8 sampai dengan 6.5 (100%)
Koefisien partisi (n-
oktanol/air)
:
:
:
:
:
:
:
:
:
:
:
:
:
Titik didih
:
100°C (212°F)
Flamabilitas
(padatan, gas)
:
Tidak tersedia.
Batas ledakan
:
Tidak tersedia.
9. Sifat Fisika dan Kimia
Produk TERJUAL
Penggunaan produk dicairkan
Cairan.
Hijau [Terang]
Mirip-wewangian
7 sampai dengan 8
> 100°C
Suhu penguraian
:
Tidak tersedia.
903422-01
Halaman: 4/7
ECO-STAR PRO SILK
9. Sifat Fisika dan Kimia
Kekentalan
Tidak tersedia.
:
Ambang bau
:
Tidak tersedia.
Hasil peruraian yang
berbahaya
Kondisi untuk dihindarkan
Tidak ada data khusus.
Pada kondisi penyimpanan dan penggunaan yang normal, produk-produk
penguraian-hayati yang berbahaya seharusnya tidak terproduksi.
Produk ini stabil.
Stabilitas
Tidak tersedia.
:
:
:
Bahan untuk dihindari
:
Kemungkinan reaksi yang
berbahaya
:
Dibawah kondisi penyimpanan dan penggunaan yang normal, reaksi yang
berbahaya tidak akan terjadi.
10. Stabilitas dan Reaktifitas
Produk TERJUAL
Data toksisitas
Nama produk/bahan
Hasil
Spesies
Dosis
Tidak diketahui efek signifikan atau bahaya kritis.
Karsinogenisitas
:
Tidak diketahui efek signifikan atau bahaya kritis.
Mutagenisitas
:
Tidak diketahui efek signifikan atau bahaya kritis.
Teratogenisitas
:
Toksisitas kronis
Rute Paparan
:
Kontak kulit, Kontak mata, Penghirupan, Tertelan
Toksisitas akut
Penghirupan
:
Tidak diketahui efek signifikan atau bahaya kritis.
Tidak diketahui efek signifikan atau bahaya kritis.
:
Tertelan
Kontak kulit
:
Menyebabkan iritasi kulit ringan.
Menyebabkan kerusakan serius pada mata.
:
Kontak mata
11. Informasi Toksikologi
Gejala
Kontak kulit
Tertelan
Penghirupan
Tidak ada data khusus.
Tidak ada data khusus.
Gejala-gejala gangguan kesehatan mungkin
akan meliputi:
iritasi
kemerahan
:
:
:
Kontak mata
:
Gejala-gejala gangguan kesehatan mungkin
akan meliputi:
sakit/nyeri
berair
kemerahan
Produk TERJUAL
Penggunaan produk dicairkan
Tidak ada data khusus.
Tidak ada data khusus.
Tidak ada data khusus.
Tidak ada data khusus.
Tidak diketahui efek signifikan atau bahaya
kritis.
Tidak diketahui efek signifikan atau bahaya
kritis.
Tidak diketahui efek signifikan atau bahaya
kritis.
Tidak diketahui efek signifikan atau bahaya
kritis.
Senyawa amonium kuaterner
LC50 Penghirupan
Debu dan kabut
Tikus besar
>45 mg/l
LD50 Dermal
Tikus besar
>2000 mg/kg
LD50 Oral
Tikus besar
>2000 mg/kg
ISOPROPIL ALKOHOL
LC50 Penghirupan Uap
Tikus besar
30 mg/l
LD50 Dermal
Kelinci
12870 mg/kg
LD50 Oral
Tikus besar
4710 mg/kg
903422-01
Halaman: 5/7
ECO-STAR PRO SILK
11. Informasi Toksikologi
Efek-efek perkembangan
selama masa pertumbuhan
:
Tidak diketahui efek signifikan atau bahaya kritis.
Efek-efek kesuburan
:
Tidak diketahui efek signifikan atau bahaya kritis.
Mobilitas dalam tanah
Tidak tersedia.
:
LogP
ow
BCF
Potensial
Potensi bioakumulasi
Efek merugikan lainnya
:
Tidak diketahui efek signifikan atau bahaya kritis.
Nama produk/bahan
Efek keracunan pada organisme air dan darat
Nama produk/bahan
Spesies
Hasil
Pemaparan
Persistensi dan kemudahan terurai
Nama produk/bahan
Uji
Dosis
Hasil
Zat inokulasi
Ekotoksisitas
:
Bahan ini toksik bagi kehidupan air dengan efek yang berakhir lama.
12. Informasi Ekologi
Produk TERJUAL
Senyawa amonium kuaterner
Kronis EC50 0.32 mg/l
Dafnia
48 jam
ISOPROPIL ALKOHOL
Akut LC50 9640 mg/l
Ikan
96 jam
Tidak tersedia.
Senyawa amonium kuaterner
rendah
ISOPROPIL ALKOHOL
0.05
rendah
Hindari pembuangan. Upayakan untuk
menggunakan produk seluruhnya sesuai dengan
maksud penggunaannya. Pembuangan harus
sesuai dengan hukum dan peraturan yang
berlaku di tingkat regional, nasional dan lokal.
:
Metode
pembuangan
13. Pertimbangan Pembuangan/Pemusnahan
Produk TERJUAL
Penggunaan produk dicairkan
Produk diencerkan dapat disalurkan ke
saluran pembuangan sanitasi Buang
kemasan kosong di tempat sampah
Nomor PBB Nama pengapalan yang sesuai
Penggolongan
Informasi
pengaturan
PG*
Informasi tambahan
PG* : Kelompok pengemasan
Lihat dokumen pengapalan untuk informasi transportasi tertentu.
14. Informasi Transportasi
Produk TERJUAL
Penggunaan produk dicairkan
Tidak dimaksudkan untuk
transportasi.
Kelas ADR/RID
Tidak diatur.
Kelas IMDG
Tidak diatur.
903422-01
Halaman: 6/7
ECO-STAR PRO SILK
15. Informasi yang berkaitan dengan Regulasi
Regulasi tentang
lingkungan, kesehatan
dan keamanan untuk
produk tersebut
:
Produk TERJUAL
Penggunaan produk dicairkan
Sejauh diketahui tidak ada peraturan nasional
atau kedaerahan spesifik yang berlaku untuk
produk ini (termasuk bahan-bahan produk
tersebut).
Sejauh diketahui tidak ada peraturan
nasional atau kedaerahan spesifik yang
berlaku untuk produk ini (termasuk bahan-
bahan produk tersebut).
Sejarah / Riwayat
Tanggal terbitan
Informasi di atas diyakini benar sehubungan dengan formula yang digunakan untuk memproduksi produk di
negara asal. Sebagai data, standar, dan perubahan peraturan, dan ketentuan penggunaan dan penanganan
berada di luar kendali kami, TIDAK ADA GARANSI, TERSURAT MAUPUN TERSIRAT, DIBUAT SEBAGAI
KELENGKAPAN ATAU AKURASI LANJUTAN DARI INFORMASI INI.
Pemberitahuan kepada pembaca
Tanggal terbitan
sebelumnya
:
:
16. Informasi Lain
Referensi
Disiapkan oleh
:
Urusan peraturan
Tidak tersedia.
17 Apr 2013
Tidak ada validasi sebelumnya
903422-01
Halaman: 7/7
- Informasi leaflet untuk produk ini saat ini tidak tersedia, Anda dapat mengirim permintaan untuk layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami mampu mendapatkannya.
Meminta selebaran informasi untuk masyarakat umum.
Dokumen dalam bahasa lain yang tersedia baik paman
- Akses ke dokumen ini hanya tersedia untuk pengguna terdaftar.
Daftar sekarang untuk akses penuh
21-2-2019

"Alternative" anti-scale processes: ANSES's recommendations
Today ANSES is publishing its opinion and report on so-called alternative anti-scale (Alt-AS) processes in drinking water distribution systems. The Agency stresses first of all that Alt-AS manufacturers and distributors have a responsibility to provide evidence of the safety and effectiveness of the processes and products they market, and expresses its disappointment at the limited data available in this regard.
France - Agence Nationale du Médicament Vétérinaire
18-2-2019

Health Canada recommends that children and youth not use cough and cold products that contain opioids
OTTAWA - The Government of Canada is committed to better informing Canadians about the risks of health products that contain opioids. Following a safety review of cough and cold products containing opioids, Health Canada is advising that Canadian children and adolescents (under 18 years of age) should not use cough and cold products containing codeine, hydrocodone and normethadone, as a precautionary measure.
Health Canada
15-2-2019

Food allergies: improve information to prevent risks
With the constant changes in eating habits and the marketing of novel foods, food allergies continue to be a public health concern. As a result of its expert assessment work, ANSES found that there was a lack of data on the prevalence of food allergies in France. The Agency therefore delivers a series of recommendations to ensure better monitoring of food allergies, and recommends providing better information to doctors as well as to consumers subject to food allergies.
France - Agence Nationale du Médicament Vétérinaire
8-2-2019

Bee protection: ANSES makes recommendations to strengthen the regulatory framework
As part of the Government's action plan on plant protection products and reduced dependence on pesticides in agriculture, ANSES is today publishing the results of its expert appraisal and its recommendations to strengthen the regulatory framework for the protection of bees and other pollinating insects. The aim of these recommendations is to further reduce bee exposure to plant protection products.
France - Agence Nationale du Médicament Vétérinaire
5-2-2019

Evaluation of confirmatory data following the Article 12 MRL review for spinosad
Published on: Mon, 04 Feb 2019 The applicant Dow AgroSciences Ltd submitted a request to the competent national authority in the Netherlands to evaluate the confirmatory data that were identified for spinosad in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. The data gaps related to residue trials on globe artichokes, flowering brassica and the nature of residues in processed commodities were satisfactorily addressed. A new feedi...
Europe - EFSA - European Food Safety Authority EFSA Journal
2-2-2019

Evaluation of confirmatory data following the Article 12 MRL review for imazamox
Published on: Fri, 01 Feb 2019 The applicant BASF SE submitted a request to the competent national authority in France to evaluate the confirmatory data that were identified for imazamox in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, the applicant submitted new residue trials on rice. Since the number of trials was not sufficient, the data gap was considered only partially addressed. The remaining dat...
Europe - EFSA - European Food Safety Authority EFSA Journal
1-2-2019

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl
Published on: Thu, 31 Jan 2019 The EFSA FEEDAP Panel previously (2016) could not conclude on the safety of certain concentrated liquid l‐lysine (base), l‐lysine monohydrochloride (HCl) and l‐lysine sulfate products manufactured using different strains of Corynebacterium glutamicum. New information on the safety of these products was provided by the applicant. The recipient strain C. glutamicum KCTC 12307BP qualifies for qualified presumption of safety (QPS) approach for safety assessment, the genetic mo...
Europe - EFSA - European Food Safety Authority EFSA Journal
25-1-2019

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified to EFSA until September 2018
Published on: Thu, 24 Jan 2019 The qualified presumption of safety (QPS) procedure was developed to provide a harmonised generic pre‐evaluation to support safety risk assessments of biological agents performed by EFSA's Scientific Panels. The taxonomic identity, body of knowledge, safety concerns and antimicrobial resistance were assessed. Safety concerns identified for a taxonomic unit are, where possible and reasonable in number, reflected by ‘qualifications’ which should be assessed at the strain lev...
Europe - EFSA - European Food Safety Authority EFSA Journal
23-1-2019

ANSES recommends improving baby diaper safety
Today, ANSES published its assessment of the risks of chemicals found in baby diapers. Based on tests conducted on disposable diapers and their use, the Agency’s assessment highlighted several chemicals for which safety threshold values were exceeded. With regard to the possible risks of these chemicals to baby health, ANSES recommends eliminating these latter or reducing their levels as much as possible in disposable diapers.
France - Agence Nationale du Médicament Vétérinaire
22-1-2019

Modification of the existing maximum residue levels for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds
Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Isagro S.p.A submitted a request to the competent national authority in Italy to modify the existing maximum residue levels (MRLs) for the active substance tetraconazole in various crops and animal commodities. The data submitted in support of the request were found to be sufficient to derive MRL proposals for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds. Adequate analytical me...
Europe - EFSA - European Food Safety Authority EFSA Journal
17-1-2019

Genotoxicity assessment of chemical mixtures
Published on: Wed, 16 Jan 2019 This document provides guidance for communicators on how to communicate the various expressions of uncertainty described in EFSA's document: ‘Guidance on uncertainty analysis in scientific assessments’. It also contains specific guidance for assessors on how best to report the various expressions of uncertainty. The document provides a template for identifying expressions of uncertainty in scientific assessments and locating the specific guidance for each expression. The g...
Europe - EFSA - European Food Safety Authority EFSA Journal
17-1-2019

Guidance on Communication of Uncertainty in Scientific Assessments
Published on: Wed, 16 Jan 2019 This document provides guidance for communicators on how to communicate the various expressions of uncertainty described in EFSA's document: ‘Guidance on uncertainty analysis in scientific assessments’. It also contains specific guidance for assessors on how best to report the various expressions of uncertainty. The document provides a template for identifying expressions of uncertainty in scientific assessments and locating the specific guidance for each expression. The g...
Europe - EFSA - European Food Safety Authority EFSA Journal
16-1-2019

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying
Published on: Mon, 14 Jan 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of B‐Act® when used in feed for turkeys for fattening, reared for breeding and minor poultry species for fattening or raised for laying. B‐Act® is a preparation containing viable spores of a Bacillus licheniformis strain. This species is considered by EFSA to be suitable for the qua...
Europe - EFSA - European Food Safety Authority EFSA Journal
16-1-2019

Software for Benchmark Dose Modelling
Published on: Mon, 14 Jan 2019 In specific contract No 7 issued under the framework agreement OC/EFSA/AMU/2015/02, EFSA requested Open Analytics to extend the Web application for Benchmark Dose Modelling built under specific contracts No 3 and No 4. The Web application is further developed in R with focus on creating a graphical module to evaluate model fit and to modify specific plot settings, as specified in the Technical Annex to Specific Contract No 7. The web application includes the latest develop...
Europe - EFSA - European Food Safety Authority EFSA Journal
12-1-2019

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species
Published on: Fri, 11 Jan 2019 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the application for renewal of authorisation of organic form of selenium produced by Saccharomyces cerevisiae NCYC R397 (Alkosel®) for all animal species. The FEEDAP Panel has delivered two opinions (on 2007 and 2016) on the safety and efficacy of the additive. The additive is characterised as organic selenium mainly selenomethionine (63%); it was ini...
Europe - EFSA - European Food Safety Authority EFSA Journal
12-1-2019

Safety and efficacy of HOSTAZYM® X (endo‐1,4‐beta‐xylanase) as a feed additive for rabbits for fattening
Published on: Fri, 11 Jan 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for rabbits for fattening. HOSTAZYM® X contains endo‐1,4‐beta‐xylanase produced by a strain of Trichoderma citrinoviride and is available in liquid and solid formulations. It is authorised as a feed additive for chickens for fattening, turkeys f...
Europe - EFSA - European Food Safety Authority EFSA Journal
10-1-2019

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)
Published on: Wed, 09 Jan 2019 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with a genetically modified strain of Trichoderma reesei by Danisco US Inc. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organic solids (TOS) are removed by distill...
Europe - EFSA - European Food Safety Authority EFSA Journal
8-1-2019

Monitoring sales of veterinary antimicrobials
Veterinary antimicrobial sales have been monitored annually by the Agency since 1999. This monitoring is based on the recommendations in Chapter 6.8 of the OIE's 2016 Terrestrial Animal Health Code "Monitoring of the quantities and usage patterns of antimicrobial agents used in food-producing animals".
France - Agence Nationale du Médicament Vétérinaire
7-1-2019

ANSES COLLECTIVE EXPERT APPRAISAL: SUMMARY AND CONCLUSIONS Regarding the "expert appraisal for recommending occupational exposure limits for chemical agents" - Assessment of health effects and methods for the measurement of exposure levels in wo
France - Agence Nationale du Médicament Vétérinaire
22-12-2018

Modification of the existing maximum residue level for captan in hops
Published on: Fri, 21 Dec 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant ADAMA Agriculture BV on behalf of ADAMA Makhteshim Ltd. submitted a request to the competent national authority in the Netherlands to modify the existing maximum residue level for the active substance captan in hops. The data submitted in support of the request were found to be insufficient to conclude whether the existing residue definitions are appropriate for hops. Although the number of residue ...
Europe - EFSA - European Food Safety Authority EFSA Journal
14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection
Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...
Europe - EFSA - European Food Safety Authority Publications
13-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation
Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce E. coli O157:H7 outbreak investigation
FDA - U.S. Food and Drug Administration
12-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to improve drug quality through vigilant oversight of data integrity and good manufacturing practice
FDA releases guidance with recommendations for drug manufacturers regarding good manufacturing practices and data integrity
FDA - U.S. Food and Drug Administration
12-12-2018

Grant agreement for piloting the Framework Partnership Agreement between the National data provider organisations in France and EFSA – Final report
Published on: Tue, 11 Dec 2018 The main goal of the Framework Partnership Agreement project is to put in place a relevant organisation in order to improve gathering, checking, storage and providing of data from national monitoring programs to EFSA. By accepting to participate in the pilot project, France has committed to implement several enhancement actions on the overall system of data collection and submission. This report describes the results of the implementations of these measures and presents th...
Europe - EFSA - European Food Safety Authority Publications
6-2-2019

Today, the @US_FDA issued a Letter to Healthcare Providers about diagnosing and treating BIA-ALCL. Click to read more about the #FDA's recommendations: https://go.usa.gov/xENj4 #MedicalDevicepic.twitter.com/szwLQ8FvxA
Today, the @US_FDA issued a Letter to Healthcare Providers about diagnosing and treating BIA-ALCL. Click to read more about the #FDA's recommendations: https://go.usa.gov/xENj4 #MedicalDevice pic.twitter.com/szwLQ8FvxA
FDA - U.S. Food and Drug Administration
31-1-2019

Today @US_FDA issued a safety communication to providers and patients about the risks of air-in-line when using infusion pumps, rapid infusers, and fluid warmers. Find out more about the risks and #FDA recommendations: https://go.usa.gov/xE9g7 ##Medi
Today @US_FDA issued a safety communication to providers and patients about the risks of air-in-line when using infusion pumps, rapid infusers, and fluid warmers. Find out more about the risks and #FDA recommendations: https://go.usa.gov/xE9g7 # #MedicalDevice pic.twitter.com/lLIyoG6680
FDA - U.S. Food and Drug Administration
7-1-2019

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow
Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow
Europe - EMA - European Medicines Agency
7-1-2019

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake
Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake
Europe - EMA - European Medicines Agency
7-1-2019

Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes
Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes
Europe - EMA - European Medicines Agency
7-1-2019

Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow
Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow
Europe - EMA - European Medicines Agency
7-1-2019

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1
Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1
Europe - EMA - European Medicines Agency
4-1-2019

New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 November 2018 PRAC
New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 November 2018 PRAC
Europe - EMA - European Medicines Agency
19-12-2018

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 December 2018
Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 December 2018
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow
Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes
Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells
Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes
Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts
Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes
Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells
Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue
Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts
Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens
Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin
Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)
Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)
Europe - EMA - European Medicines Agency
18-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro
Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product
Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette
Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid
Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts
Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue
Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Four in vitro transcribed mRNA molecules each encoding one tumour antigen
Scientific recommendation on classification of advanced therapy medicinal products: Four in vitro transcribed mRNA molecules each encoding one tumour antigen
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of defective myoblasts from a Duchenne Muscular Dystrophy patient with normal myoblasts
Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of defective myoblasts from a Duchenne Muscular Dystrophy patient with normal myoblasts
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Autologous suspension of blood-derived endothelial and hematopoietic stem/progenitor cells
Scientific recommendation on classification of advanced therapy medicinal products: Autologous suspension of blood-derived endothelial and hematopoietic stem/progenitor cells
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Autologous anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cells
Scientific recommendation on classification of advanced therapy medicinal products: Autologous anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cells
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells
Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Non-replicating recombinant adeno-associated virus carrying a fragment of the Channelrhodopsin-2 (ChR2) protein
Scientific recommendation on classification of advanced therapy medicinal products: Non-replicating recombinant adeno-associated virus carrying a fragment of the Channelrhodopsin-2 (ChR2) protein
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated virus (AAV) vector encoding genes from an algae channel rhodopsin
Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated virus (AAV) vector encoding genes from an algae channel rhodopsin
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Four independent DNA plasmid vectors encoding HBV antigens and human interleukin-12
Scientific recommendation on classification of advanced therapy medicinal products: Four independent DNA plasmid vectors encoding HBV antigens and human interleukin-12
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Autologous fibroblasts expanded in vitro
Scientific recommendation on classification of advanced therapy medicinal products: Autologous fibroblasts expanded in vitro
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Live attenuated Listeria monocytogenes transfected with plasmids encoding HPV fusion protein
Scientific recommendation on classification of advanced therapy medicinal products: Live attenuated Listeria monocytogenes transfected with plasmids encoding HPV fusion protein
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Autologous concentrated bone marrow
Scientific recommendation on classification of advanced therapy medicinal products: Autologous concentrated bone marrow
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Collagenase enzyme from Clostridium histolyticum
Scientific recommendation on classification of advanced therapy medicinal products: Collagenase enzyme from Clostridium histolyticum
Europe - EMA - European Medicines Agency
12-12-2018

Scientific recommendation on classification of advanced therapy medicinal products: Autologous ex vivo expanded regulatory T lymphocytes with the cell marker profile of CD3+, CD4+, CD25high, CD127-, FoxP3+
Scientific recommendation on classification of advanced therapy medicinal products: Autologous ex vivo expanded regulatory T lymphocytes with the cell marker profile of CD3+, CD4+, CD25high, CD127-, FoxP3+
Europe - EMA - European Medicines Agency